Cancer

Cover image for Cancer

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.901

ISI Journal Citation Reports © Ranking: 2013: 38/203 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

VIEW

  1. 1 - 100
  2. 101 - 147
  1. Original Articles

    1. Discipline

      Disparities Research
      Racial/ethnic disparities in knowledge about one's breast cancer characteristics

      Rachel A. Freedman, Elena M. Kouri, Dee W. West and Nancy L. Keating

      Article first published online: 26 JAN 2015 | DOI: 10.1002/cncr.28977

      Women's knowledge about their breast cancer characteristics was generally poor for all patients, and minority, less educated, and older women were the least likely to know and correctly report characteristics.

  2. Commentary

    1. Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: The reverse of the Will Rogers phenomenon?

      Emmanouil Fokas, Torsten Liersch, Rainer Fietkau, Werner Hohenberger, Clemens Hess, Heinz Becker, Rolf Sauer, Christian Wittekind and Claus Rödel

      Article first published online: 21 JAN 2015 | DOI: 10.1002/cncr.29260

      Although downstaging after neoadjuvant treatment is increasingly used as a prognostic factor and surrogate endpoint in clinical trials, the current study directly questions its value after preoperative treatment when assessing treatment efficacy.

  3. Original Articles

    1. Discipline

      Clinical Trials
      Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial

      John D. Hainsworth, Gedske Daugaard, Thierry Lesimple, Gerdt Hübner, F. Anthony Greco, Michael J. Stahl, Christian Meyer Zum Büschenfelde, Djelila Allouache, Nicolas Penel, Poul Knoblauch and Karim S. Fizazi

      Article first published online: 21 JAN 2015 | DOI: 10.1002/cncr.29229

      The addition of belinostat to combined paclitaxel and carboplatin does not improve the progression-free survival of patients with carcinoma of unknown primary site who receive first-line therapy, although patients who receive belinostat have a higher investigator-assessed response rate.

    2. Disease Site

      Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Low expression of chloride channel accessory 1 predicts a poor prognosis in colorectal cancer

      Bo Yang, Lin Cao, Jiaen Liu, Yanjie Xu, Gillian Milne, Wanhei Chan, Steven D. Heys, Colin D. McCaig and Jin Pu

      Article first published online: 20 JAN 2015 | DOI: 10.1002/cncr.29235

      The level of chloride channel accessory 1 expression may be a potential predictor of prognosis in primary human colorectal cancer. Low expression of chloride channel accessory 1 predicts disease recurrence and lower survival, and this has implications for the selection of patients most likely to need and benefit from adjuvant chemotherapy.

    3. Discipline

      Medical Oncology
      Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration

      Doreen A. Ezeife, Tony H. Truong, Daniel Y. C. Heng, Sylvie Bourque, Stephen A. Welch and Patricia A. Tang

      Article first published online: 20 JAN 2015 | DOI: 10.1002/cncr.29246

      The drug approval timeline, from regulatory agency submission to approval, is 3 months shorter for the US Food and Drug Administration than for Health Canada. The median time from Health Canada approval to the placement of a drug on a provincial formulary is 16.7 months.

    4. Disease Site

      Breast Disease
      Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium

      Kimberly H. Allison, Linn A. Abraham, Donald L. Weaver, Anna N. A. Tosteson, Heidi D. Nelson, Tracy Onega, Berta M. Geller, Karla Kerlikowske, Patricia A. Carney, Laura E. Ichikawa, Diana S. M. Buist and Joann G. Elmore

      Article first published online: 20 JAN 2015 | DOI: 10.1002/cncr.29199

      Based on diagnostic results of breast biopsies from the BCSC from women undergoing mammography between 1996 and 2008, the frequencies of biopsy after screening mammography did not change over time, whereas diagnoses of DCIS and invasive cancer increased, suggesting more targeted use of biopsy. Among biopsies following mammography, women with dense breasts or family history of breast cancer were more likely to have high-risk lesions or invasive cancer.

  4. Review Articles

    1. The role of postoperative chemoradiation for oropharynx carcinoma: A critical appraisal of the published literature and National Comprehensive Cancer Network guidelines

      Parul Sinha, Jay F. Piccirillo, Dorina Kallogjeri, Edward L. Spitznagel and Bruce H. Haughey

      Article first published online: 14 JAN 2015 | DOI: 10.1002/cncr.29242

      The National Comprehensive Cancer Network's category 1 recommendation for the addition of chemotherapy to postoperative radiation in patients with oropharynx cancer is based on a hypothesis-generating subset analysis, and not high-level evidence. The current National Comprehensive Cancer Network guideline for adjuvant therapy does not inform human papillomavirus-related oropharynx cancer management.

  5. Original Articles

    1. Disease Site

      Breast Disease
      Flat epithelial atypia and risk of breast cancer: A Mayo cohort study

      Samar M. Said, Daniel W. Visscher, Aziza Nassar, Ryan D. Frank, Robert A. Vierkant, Marlene H. Frost, Karthik Ghosh, Derek C. Radisky, Lynn C. Hartmann and Amy C. Degnim

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29243

      Based on its cytologic features, and its cooccurrence with atypical hyperplasia and breast cancer, flat epithelial atypia has been proposed as a precursor lesion on the pathway to the development of breast cancer. However, it appears to be a benign proliferative finding of the breast that does not convey an independent risk of future breast cancer.

    2. Head and Neck Disease
      Pretreatment Dysphagia Inventory and videofluorographic swallowing study as prognostic indicators of early survival outcomes in head and neck cancer

      Chan Joo Yang, Jong-Lyel Roh, Kyoung Hyo Choi, Min-Ju Kim, Seung-Ho Choi, Soon Yuhl Nam and Sang Yoon Kim

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29245

      Associations between pretreatment MD Anderson Dysphagia Inventory or videofluorographic swallowing study results and treatment outcomes are evaluated in patients with head and neck squamous cell carcinoma. The total score, global assessment, and subdomains of the MD Anderson Dysphagia Inventory are significantly predictive of early survival outcomes in patients with head and neck squamous cell carcinoma.

    3. Genitourinary Disease
      Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer

      Stéphane Terry, Nathalie Nicolaiew, Victor Basset, Fannie Semprez, Pascale Soyeux, Pascale Maillé, Francis Vacherot, Guillaume Ploussard, Arturo Londoño-Vallejo, Alexandre de la Taille and Yves Allory

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29233

      The development of biomarkers may be helpful to estimate tumor heterogeneity and stratify prostate cancer patients in terms of risk of progression. The results from this study suggest that ERG and TFF3 characterize 2 distinct subsets of prostate cancer, including a more aggressive subgroup for TFF3 tumors that express SPINK1, supporting a rationale of screening for these biomarkers for prognostic purposes and molecular subtyping of the disease.

    4. Discipline

      Disparities Research
      Patient navigation based on predictive modeling decreases no-show rates in cancer care

      Sanja Percac-Lima, Patrick R. Cronin, David P. Ryan, Bruce A. Chabner, Emily A. Daly and Alexandra B. Kimball

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29236

      Targeted patient navigation over the telephone to patients determined by predictive modeling to be at high risk of being no-shows for appointments can effectively and substantially increase patient adherence to cancer clinic appointments and improve adherence to cancer care.

    5. Radiation Oncology
      Proton therapy for low-grade gliomas: Results from a prospective trial

      Helen A. Shih, Janet C. Sherman, Lisa B. Nachtigall, Mary K. Colvin, Barbara C. Fullerton, Juliane Daartz, Barbara K. Winrich, Tracy T. Batchelor, Lauren T. Thornton, Sarah M. Mancuso, Michele K. Saums, Kevin S. Oh, William T. Curry, Jay S. Loeffler and Beow Y. Yeap

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29237

      Patients with low-grade glioma can safely and effectively receive proton radiation therapy with no added neurocognitive impairment or quality-of-life decrement based on early experience. Radiation dose to the pituitary correlates with early neuroendocrine dysfunction.

    6. Disease Site

      Head and Neck Disease
      Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey

      David I. Rosenthal, Abdallah S. R. Mohamed, Randal S. Weber, Adam S. Garden, Parag R. Sevak, Merril S. Kies, William H. Morrison, Jan S. Lewin, Adel K. El-Naggar, Lawrence E. Ginsberg, Esengul Kocak-Uzel, K. Kian Ang and Clifton David Fuller

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29241

      Total laryngectomy followed by postoperative radiotherapy can produce long-term cancer control and survival for patients with T4 larynx cancer. The selection of patients for nonsurgical initial treatment should be done carefully because of significant rates of functional impairment and locoregional failure.

    7. An audit and feedback system for effective quality improvement in head and neck surgery: Can we become better surgeons?

      Carol M. Lewis, Marcus M. Monroe, Dianna B. Roberts, Amy C. Hessel, Stephen Y. Lai and Randal S. Weber

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29238

      After an initial audit, individual surgeons are provided with their own performance data and anonymized departmental performance. A subsequent audit reveals a significant decrease in the postoperative length of stay and the prevalence of negative performance indicators.

    8. Discipline

      Clinical Trials
      Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up

      Jorge E. Cortes, Hagop M. Kantarjian, Delphine Rea, Meir Wetzler, Jeffrey H. Lipton, Luke Akard, H. Jean Khoury, Mauricette Michallet, Agnès Guerci-Bresler, Charles Chuah, Andrzej Hellmann, Raghunadharao Digumarti, Purvish M. Parikh, Laurence Legros, Krzysztof Warzocha, Michele Baccarani, Elizabeth Li, Mihaela Munteanu and Franck E. Nicolini

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29240

      Final efficacy and safety data for omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia with at least 24 months of follow-up are presented from the pivotal Chronic Myeloid Leukemia 300 study. The results suggest that the long-term administration of omacetaxine is feasible and that omacetaxine provides durable hematologic and cytogenetic responses in some patients.

    9. Radiation Oncology
      A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non–small cell lung cancer (NSCLC)

      Wataru Takahashi, Mio Nakajima, Naoyoshi Yamamoto, Hideomi Yamashita, Keiichi Nakagawa, Tadaaki Miyamoto, Hiroshi Tsuji, Tadashi Kamada and Takehiko Fujisawa

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29195

      Carbon ion therapy shows promise as a monotherapy in patients with inoperable locally advanced non–small cell lung cancer who are not candidates for concurrent chemoradiotherapy. We achieved 51.9% overall 2-year survival rates, with this modality.

    10. Pediatric Oncology
      EZH2 expression is a prognostic factor in childhood intracranial ependymoma: A Canadian Pediatric Brain Tumor Consortium study

      Amanda M. Li, Christopher Dunham, Uri Tabori, Anne-Sophie Carret, P. Daniel McNeely, Donna Johnston, Lucie Lafay-Cousin, Beverly Wilson, David D. Eisenstat, Nada Jabado, Shayna Zelcer, Mariana Silva, Katrin Scheinemann, Christopher Fryer, Glenda Hendson, Abbas Fotovati, Cynthia Hawkins, Stephen Yip, Sandra E. Dunn and Juliette Hukin

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29198

      Expression levels of several biomarkers are investigated in pediatric intracranial ependymomas, and enhancer of zeste homolog 2 (EZH2) expression is independently associated with poor survival. Thus, EZH2 is identified as a novel prognostic factor in pediatric intracranial ependymoma.

    11. Disease Site

      Gastrointestinal Disease
      Clinical outcomes of patients with advanced gastrointestinal stromal tumors: Safety and efficacy in a worldwide treatment-use trial of sunitinib

      Peter Reichardt, Yoon-Koo Kang, Piotr Rutkowski, Jochen Schuette, Lee S. Rosen, Beatrice Seddon, Suayib Yalcin, Hans Gelderblom, Charles C. Williams Jr, Elena Fumagalli, Guido Biasco, Herbert I. Hurwitz, Pamela E. Kaiser, Kolette Fly, Ewa Matczak, Liang Chen, Maria José Lechuga and George D. Demetri

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29220

      Final results from a worldwide treatment-use study of sunitinib in gastrointestinal stromal tumor (GIST) add to the existing body of evidence supporting the long-term safety and efficacy of sunitinib in an international population of patients with advanced GIST after failure on first-line imatinib who were ineligible for other sunitinib clinical trials. These data expand results reported in the more restricted and selected population of patients accrued to the phase 3 study of sunitinib in GIST.

  6. Review Articles

    1. Screening and early detection efforts in lung cancer

      Neeti M. Kanodra, Gerard A. Silvestri and Nichole T. Tanner

      Article first published online: 13 JAN 2015 | DOI: 10.1002/cncr.29222

      Since publication of the National Lung Screening Trial, several professional organizations, including the US Preventive Services Task Force, have published guidelines recommending low-dose computed tomography for screening in asymptomatic, high-risk individuals. Recommendations for lung cancer screening include risks, benefits, costs, and future directions in the efforts for early detection.

  7. Original Articles

    1. Discipline

      Quality of Life
      Current unmet needs of cancer survivors: Analysis of open-ended responses to the American Cancer Society Study of Cancer Survivors II

      Mary Ann Burg, Gail Adorno, Ellen D. S. Lopez, Victoria Loerzel, Kevin Stein, Cara Wallace and Dinghy Kristine B. Sharma

      Article first published online: 12 JAN 2015 | DOI: 10.1002/cncr.28951

      Qualitative techniques are used to code themes of unmet needs from open-ended responses to a large survey of cancer survivors. Sixteen themes of unmet needs are identified.

    2. Disease Site

      Gastrointestinal Disease
      The colorectal cancer mortality-to-incidence ratio as an indicator of global cancer screening and care

      Vasu Sunkara and James R. Hébert

      Article first published online: 8 JAN 2015 | DOI: 10.1002/cncr.29228

      The mortality-to-incidence ratio helps to identify disparities in colorectal cancer screening and treatment internationally. It has the potential to be an indicator of the long-term success of colorectal cancer surveillance programs, with possible extension to other cancer types.

    3. Head and Neck Disease
      Second primary head and neck cancer after Hodgkin lymphoma: A population-based study of 44,879 survivors of Hodgkin lymphoma

      Amit K. Chowdhry, Colin McHugh, Chunkit Fung, Sughosh Dhakal, Louis S. Constine and Michael T. Milano

      Article first published online: 8 JAN 2015 | DOI: 10.1002/cncr.29231

      There is a significantly increased risk of salivary and nonsalivary head and neck cancer after a diagnosis of Hodgkin lymphoma. Survivors of Hodgkin lymphoma with squamous cell head and neck cancer experience worse survival outcomes.

    4. Discipline

      Epidemiology
      Teenage acne and cancer risk in US women: A prospective cohort study

      Mingfeng Zhang, Abrar A. Qureshi, Renée T. Fortner, Susan E. Hankinson, Qingyi Wei, Li-E Wang, A. Heather Eliassen, Walter C. Willett, David J. Hunter and Jiali Han

      Article first published online: 8 JAN 2015 | DOI: 10.1002/cncr.29216

      We identify a history of teenage acne as a novel risk factor for melanoma independent of the previously identified risk factors. Our findings may provide novel insight into the etiology of melanoma. In addition, a history of acne may be an early-stage marker of high androgen levels, which might have potential importance to help identify populations at higher risk of hormone-related cancers.

    5. Disease Site

      Endocrine Disease
      Trends in imaging after diagnosis of thyroid cancer

      Jaime L. Wiebel, Mousumi Banerjee, Daniel G. Muenz, Francis P. Worden and Megan R. Haymart

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29210

      Using the Surveillance, Epidemiology, and End Results-Medicare database, the authors report that despite a rise in low-risk differentiated thyroid cancer, there has been a significant increase in the use of postdiagnosis imaging studies over the past 20 years. This is true for the 3 major imaging modalities used (neck ultrasound, radioiodine scan, and positron emission tomography), with the most dramatic increase noted in the use of positron emission tomography after 2004.

    6. Hepatobiliary Disease
      A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma

      Mairéad G. McNamara, Lisa W. Le, Anne M. Horgan, Alex Aspinall, Kelly W. Burak, Neesha Dhani, Eric Chen, Mehrdad Sinaei, Glen Lo, Tae Kyoung Kim, Patrik Rogalla, Oliver F. Bathe and Jennifer J. Knox

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29227

      With second-line axitinib treatment, tumor control was established in 42.3% at 16 weeks. Axitinib showed encouraging tolerable clinical activity in vascular endothelial growth factor–pretreated hepatocellular carcinoma patients, but further study is indicated in a selected population incorporating potential biomarkers of response.

    7. Discipline

      Quality of Life
      Health-related quality of life in lung cancer survivors: Latent class and latent transition analysis

      Kelly M. Kenzik, Michelle Y. Martin, Mona N. Fouad and Maria Pisu

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29232

      According to responses on a health-related quality of life (HRQOL) questionnaire in the initial and survivorship phases of care, there are 4 subgroups (classes) of lung cancer survivors for which different HRQOL limitations are prominent, and survivors are unlikely to transition out of these classes during the survivorship phase. Classes have different survival profiles; thus, identifying which class survivors fall into during the initial phase of care is critical to developing supportive care strategies and improving long-term outcomes.

    8. Disparities Research
      Impact of patient and navigator race and language concordance on care after cancer screening abnormalities

      Marjory Charlot, M. Christina Santana, Clara A. Chen, Sharon Bak, Timothy C. Heeren, Tracy A. Battaglia, A. Patrick Egan, Richard Kalish and Karen M. Freund

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29221

      Patient navigator race and language concordance improves the timeliness of care after cancer screening in a minority population. Patient navigators who are diverse by race/ethnicity and multilingual may help address barriers to care and improve cancer outcomes for low-income minority populations.

    9. Health behaviors of minority childhood cancer survivors

      Melinda R. Stolley, Lisa K. Sharp, Christy C. Tangney, Linda A. Schiffer, Claudia Arroyo, Yoonsang Kim, Richard T. Campbell, Mary Lou Schmidt, Kathleen Breen, Karen E. Kinahan, Kim J. Dilley, Tara O. Henderson, Allen D. Korenblit and Katya Seligman

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29202

      The current study examined the health behaviors of minority childhood cancer survivors compared with white peers and noncancer controls. Overall, survivors were not different from controls, but minority survivors may be at a higher risk of adverse outcomes.

    10. Disease Site

      Chest and Lung Disease
      Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: The Japanese Association for Research on the Thymus Database Study

      Mitsugu Omasa, Hiroshi Date, Takashi Sozu, Tosiya Sato, Kanji Nagai, Kohei Yokoi, Tatsuro Okamoto, Norihiko Ikeda, Fumihiro Tanaka, Yoshimasa Maniwa and for the Japanese Association for Research on the Thymus

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29166

      Postoperative radiotherapy increases relapse-free survival for stage II and III thymic carcinoma. Postoperative radiotherapy does not increase relapse-free survival or overall survival for stage II or III thymoma.

    11. Discipline

      Disparities Research
      Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: Another long-term effect of cancer?

      Maria Pisu, Kelly M. Kenzik, Robert A. Oster, Patricia Drentea, Kimlin T. Ashing, Mona Fouad and Michelle Y. Martin

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29206

      One-year after diagnosis, approximately 1 in 2 survivors of lung cancer and colorectal cancer report economic hardship, especially African Americans. This disparity among lung cancer survivors is explained by differences in economic status; however, among colorectal cancer survivors, differences in economic status, cancer stage, and treatment do not account for the observed disparities.

  8. Editorial

    1. Postoperative radiotherapy: Not all thymic malignancies are created equal

      Andreas Rimner

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29164

      The key finding of Omasa et al.'s study is that postoperative radiotherapy is associated with an improvement in recurrence-free survival in patients with thymic carcinoma but not in patients with thymoma.

  9. Correspondence

    1. Sham procedure inadequate

      William Hay

      Article first published online: 6 JAN 2015 | DOI: 10.1002/cncr.29114

  10. Original Articles

    1. Disease Site

      Head and Neck Disease
      Incidence of head and neck squamous cell carcinoma among subjects at high risk of lung cancer: Results from the Pittsburgh Lung Screening Study

      Ronak Dixit, Joel L. Weissfeld, David O. Wilson, Paula Balogh, Pamela Sufka, Jill M. Siegfried, Jennifer R. Grandis and Brenda Diergaarde

      Article first published online: 5 JAN 2015 | DOI: 10.1002/cncr.29189

      Earlier diagnosis of head and neck cancer should lead to improved outcomes. However, because head and neck cancer is relatively rare, screening of the general population is impractical. Results from the current study provide a rationale for offering head and neck cancer screening along with low-dose computed tomography screening for lung cancer.

    2. Gastrointestinal Disease
      Prevalence of somatic mutl homolog 1 promoter hypermethylation in Lynch syndrome colorectal cancer

      Leticia Moreira, Jenifer Muñoz, Míriam Cuatrecasas, Isabel Quintanilla, Maria Liz Leoz, Sabela Carballal, Teresa Ocaña, María López-Cerón, Maria Pellise, Sergi Castellví-Bel, Rodrigo Jover, Montserrat Andreu, Angel Carracedo, Rosa Maria Xicola, Xavier Llor, Clement Richard Boland, Ajay Goel, Antoni Castells and Francesc Balaguer

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29190

      Somatic mutL homolog 1 (MLH1) hypermethylation occurs in up to 15% of Lynch syndrome colorectal cancers, and a meaningful proportion of potential MLH1 mutation carriers may be undiagnosed when relying on somatic MLH1 methylation for indicating germline genetic testing. This is a novel and clinically relevant result that clearly argues against the use of MLH1 methylation analysis as a negative predictor of an MLH1 germline mutation.

  11. Review Articles

    1. Therapeutic targeting of tumor suppressor genes

      Luc G. T. Morris and Timothy A. Chan

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29140

      In recent years, several promising strategies directed at tumor suppressor genes, or the pathways controlled by these genes, have emerged. Here, we describe advances in a number of different methodologies aimed at therapeutically targeting tumors driven by inactivated tumor suppressor genes.

  12. Original Articles

    1. Disease Site

      Neuro-Oncology
      Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab

      Jim Zhong, Arif N. Ali, Alfredo D. Voloschin, Yuan Liu, Walter J. Curran Jr, Ian R. Crocker and Hui-Kuo G. Shu

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29234

      Patients with recurrent glioblastoma who are treated with bevacizumab and develop hypertension as a side effect appear to demonstrate significantly better progression-free survival and overall survival. Therefore, bevacizumab-induced hypertension may be a physiologic marker of outcome in patients with recurrent glioblastoma.

    2. Discipline

      Pediatric Oncology
      Improving our understanding of the use of traditional complementary/alternative medicine in children with cancer

      Elena J. Ladas, Meiko Lin, Federico Antillion, Silvia Rivas, Guillermo Chantada, Walter Cacciavillano, Roberta Ortiz, Katja Stein, Luis Castillo, Valeria Rocha, Ligia Fu, Hilze Rodriquez and Kara M. Kelly

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29212

      We demonstrate the success of the development of a cross-cultural survey exploring the use of Traditional Complementary/Alternative Medicine (TCAM) in children with cancer. These findings will aid investigators in providing guidelines on TCAM, support the development of education and research priorities, and assist with the identification of region-specific variables related to use of TCAM.

    3. Does phase 1 trial enrollment preclude quality end-of-life care? Phase 1 trial enrollment and end-of-life care characteristics in children with cancer

      Deena R. Levine, Liza-Marie Johnson, Belinda N. Mandrell, Jie Yang, Nancy K. West, Pamela S. Hinds and Justin N. Baker

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29230

      Does phase 1 trial participation impact end-of-life care characteristics among patients with cancer? This institutional retrospective review of children with cancer demonstrated no significant differences in end-of-life characteristics among those who did and those who did not enroll in a phase 1 trial.

    4. Conditional survival in pediatric malignancies: Analysis of data from the Childhood Cancer Survivor Study and the Surveillance, Epidemiology, and End Results Program

      Ann C. Mertens, Jian Yong, Andrew C. Dietz, Erin Kreiter, Yutaka Yasui, Archie Bleyer, Gregory T. Armstrong, Leslie L. Robison and Karen Wasilewski-Masker

      Article first published online: 29 DEC 2014 | DOI: 10.1002/cncr.29170

      Overall, conditional survival is high in 5-year survivors of pediatric cancer. For health care providers, as well as for survivors and their families, this information is clinically important when counseling patients seen during long-term follow-up.

    5. Outcomes Research
      Comparison of primary and secondary breast cancers in adolescents and young adults

      Claire Sadler and Melanie Goldfarb

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29200

      Nonprimary breast cancer in female adolescents and young adults (AYAs) has different tumor characteristics, presents at a lower stage, and receives less adjuvant therapy than primary AYA female breast cancers. Second malignancy status is an independent risk factor for decreased overall survival, with an almost 10% decrease at 3 years.

    6. Quality of life and satisfaction among prostate cancer patients followed in a dedicated survivorship clinic

      Scott M. Gilbert, Rodney L. Dunn, Daniela Wittmann, Jeffrey S. Montgomery, John M. Hollingsworth, David C. Miller, Brent K. Hollenbeck, John T. Wei and James E. Montie

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29215

      Integrating patient-reported outcomes such as quality of life into the recovery care of men with prostate cancer is associated with better outcomes. These results indicate that more tailored approaches to evaluating and addressing patient-reported problems improve care and support survivorship models of care.

    7. Aspiration pneumonia after concurrent chemoradiotherapy for head and neck cancer

      Beibei Xu, Isabel J. Boero, Lindsay Hwang, Quynh-Thu Le, Vitali Moiseenko, Parag R. Sanghvi, Ezra E. W. Cohen, Loren K. Mell and James D. Murphy

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29207

      The results from this Surveillance, Epidemiology, End Results-Medicare–based study indicate that nearly 25% of elderly patients will develop aspiration pneumonia within 5 years of receiving chemoradiotherapy for head and neck cancer. These patients also have a significantly increased rate of death, suggesting that a better understanding of mitigating factors could help identify patients who are at risk for this potentially lethal complication.

    8. Disease Site

      Breast Disease
      Performance of digital screening mammography among older women in the United States

      Louise M. Henderson, Ellen S. O'Meara, Dejana Braithwaite, Tracy Onega and for the Breast Cancer Surveillance Consortium

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29214

      The specificity, positive predictive value, recall rate, and cancer-detection rate of digital screening mammography all improve with increasing age. The current results indicate that, as age increases, the proportion of women with invasive breast cancer versus ductal carcinoma in situ rises, whereas the proportion of women with positive lymph nodes decreases.

    9. Discipline

      Clinical Trials
      Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

      Edwin Choy, Yael Flamand, Sriram Balasubramanian, James E. Butrynski, David C. Harmon, Suzanne George, Gregory M. Cote, Andrew J. Wagner, Jeffrey A. Morgan, Mint Sirisawad, Chitra Mani, Francis J. Hornicek, Zhenfeng Duan and George D. Demetri

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29175

      In this phase 1 study, the histone deacetylase inhibitor abexinostat (PCI-24781) is administered in combination with doxorubicin to patients with metastatic sarcoma. The maximum tolerated dose for abexinostat is 45 mg/m2 twice daily when administered on days 1 through 5 with doxorubicin at a dose of 75 mg/m2 on day 4 of a 3-week cycle, and granulocyte-colony–stimulating factor support is mandated.

    10. Radiation Oncology
      You have full text access to this OnlineOpen article
      Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma

      Joseph M. Herman, Daniel T. Chang, Karyn A. Goodman, Avani S. Dholakia, Siva P. Raman, Amy Hacker-Prietz, Christine A. Iacobuzio-Donahue, Mary E. Griffith, Timothy M. Pawlik, Jonathan S. Pai, Eileen O'Reilly, George A. Fisher, Aaron T. Wild, Lauren M. Rosati, Lei Zheng, Christopher L. Wolfgang, Daniel A. Laheru, Laurie A. Columbo, Elizabeth A. Sugar and Albert C. Koong

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29161

      To the authors' knowledge, the current study is the first prospective multi-institutional trial evaluating the role of stereotactic body radiotherapy in patients with locally advanced pancreatic cancer. The results suggest that fractionated stereotactic body radiotherapy with gemcitabine achieves favorable toxicity, quality of life, and preliminary efficacy compared with historical data.

    11. Complementary Medicine
      Mindfulness meditation for younger breast cancer survivors: A randomized controlled trial

      Julienne E. Bower, Alexandra D. Crosswell, Annette L. Stanton, Catherine M. Crespi, Diana Winston, Jesusa Arevalo, Jeffrey Ma, Steve W. Cole and Patricia A. Ganz

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29194

      Women who are diagnosed with premenopausal breast cancer report higher levels of stress, distress, and physical symptoms and are less likely to participate in support groups than older women. In this study, a mindfulness-based intervention targeted for younger breast cancer survivors has excellent adherence and leads to significant short-term reductions in stress, physical symptoms, and inflammatory activity, with longer term benefits observed for cancer-related distress.

    12. Disease Site

      Head and Neck Disease
      Single-cycle induction chemotherapy followed by chemoradiotherapy or surgery in patients with head and neck cancer: What are the best predictors of remission and prognosis?

      Sabine Semrau, Marlen Haderlein, Daniela Schmidt, Michael Lell, Walburga Wolf, Frank Waldfahrer, Michael Uder, Heinrich Iro, Torsten Kuwert and Rainer Fietkau

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29188

      This article focuses on strategies of tumor response assessment after single-cycle chemotherapy in borderline-resectable head and neck squamous cell carcinoma before subsequent chemoradiotherapy or surgery. 18F-FDG-PET response assessment correlates better than CT-based response with endoscopic response assessment and is potentially capable of identifying more patients eligible for a conservative, organ-preserving approach than endoscopy or CT.

  13. Editorials

    1. Histone deacetylase inhibitors in cancer: What have we learnt?

      James R. Whittle and Jayesh Desai

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29177

      The authors outline the current stage in the development of histone deacetylase inhibitors in solid tumors. Despite single-agent benefit in a small number of hematologic malignancies, evidence in solid organ cancers suggests that outcomes will be more promising with combination therapy and should be the focus of future studies.

  14. Erratum

    1. You have free access to this content
  15. Original Articles

    1. Disease Site

      Hepatobiliary Disease
      Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population-based cohort study

      Jack P. Wang, Feng-Yu Kao, Chen-Yi Wu, Yi-Ping Hung, Yee Chao, Yiing-Jenq Chou and Chung-Pin Li

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29159

      Nucleos(t)ide analogues reduce the risk of hepatocellular carcinoma and overall mortality in hepatitis B carriers. The dose-response effects further strengthen the causal relationship and support the use of nucleos(t)ide analogues in patients with chronic hepatitis B.

    2. Discipline

      Disparities Research
      Are primary care providers prepared to care for survivors of breast cancer in the safety net?

      Aaron J. Dawes, Marian Hemmelgarn, David K. Nguyen, Greg D. Sacks, Sheilah M. Clayton, Jacqueline R. Cope, Patricia A. Ganz and Melinda Maggard-Gibbons

      Article first published online: 23 DEC 2014 | DOI: 10.1002/cncr.29201

      Primary care providers working in safety-net settings report low knowledge and confidence in their ability to care for survivors of breast cancer. Additional training concerning aspects of survivorship care, including compliance with American Society of Clinical Oncology guidelines, is needed before survivors can be successfully transitioned to primary care.

    3. Radiation Oncology
      Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiotherapy fractionation in patients with locoregionally advanced nasopharyngeal carcinoma

      Anne W.M. Lee, Roger K.C. Ngan, Stewart Y. Tung, Ashley Cheng, Dora L.W. Kwong, Tai-Xiang Lu, Anthony T.C. Chan, Lucy L.K. Chan, Harry Yiu, Wai-Tong Ng, Frank Wong, Kam-Tong Yuen, Stephen Yau, Foon-Yiu Cheung, Oscar S.H. Chan, Horace Choi and Rick Chappell

      Article first published online: 19 DEC 2014 | DOI: 10.1002/cncr.29208

      Preliminary results from nasopharyngeal carcinoma trial NPC-0501 demonstrate that the benefit of changing the chemotherapy schedule from a concurrent-adjuvant sequence to an induction-concurrent sequence remains uncertain, and replacing fluorouracil with capecitabine warrants further validation in view of the convenience and favorable toxicity profile of capecitabine and the at least comparable efficacy each agent. In agreement with studies on other head and neck cancers, accelerated fractionation is not recommended for patients with locoregionally advanced nasopharyngeal carcinoma who are receiving chemoradiotherapy.

  16. Review Articles

    1. Frailty in childhood cancer survivors

      Kirsten K. Ness, Gregory T. Armstrong, Mondira Kundu, Carmen L. Wilson, Tamara Tchkonia and James L. Kirkland

      Article first published online: 19 DEC 2014 | DOI: 10.1002/cncr.29211

      Young adult childhood cancer survivors are at an increased risk of frailty, a physiologic phenotype typically found among older adults. This phenotype is associated with new-onset chronic health conditions and mortality among both older adults and childhood cancer survivors. This article provides a review of the evidence documenting physiologic frailty among childhood cancer survivors and describes potential biological mechanisms for this phenotype.

  17. Original Articles

    1. Discipline

      Pediatric Oncology
      Safety and diagnostic accuracy of tumor biopsies in children with cancer

      Rodrigo B. Interiano, Amos H.P. Loh, Nathan Hinkle, Fazal N. Wahid, Alpin D. Malkan, Armita Bahrami, Jesse J. Jenkins, Shenghua Mao, Jianrong Wu, Kimberly Proctor, Victor M. Santana, Alberto S. Pappo, Robert E. Gold and Andrew M. Davidoff

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29167

      In addition to establishing the diagnosis of cancer, tumor biopsies are being increasingly used for determining the presence of molecular targets, confirming pharmacodynamic effects, and tumor banking. Nevertheless, to the authors' knowledge, the risks and accuracy of these procedures in pediatric patients with cancer are unknown. In the current review of an extensive experience, the authors found that tumor biopsies in children are associated with an acceptably low incidence of clinically relevant adverse events (<8%) and have a high diagnostic accuracy (>90%).

    2. Epidemiology
      Marital status and head and neck cancer outcomes

      Gino Inverso, Brandon A. Mahal, Ayal A. Aizer, R. Bruce Donoff, Nicole G. Chau and Robert I. Haddad

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29171

      Married patients are less likely than unmarried patients to present with metastatic oral and laryngeal cancers, more likely to receive definitive treatment across the 5 head and neck cancer sites (oral, oropharyngeal, hypopharyngeal, nasopharyngeal, and laryngeal), and less likely to die from cancers of these 5 sites. These findings suggest that spousal support may play a role in the surveillance of patients who have visual and symptomatic head and neck cancers and can lead to higher rates of treatment and better survival across all head and neck cancer types.

    3. Quality of Life
      The effects of cancer and racial disparities in health-related quality of life among older Americans: A case-control, population-based study

      Laura C. Pinheiro, Stephanie B. Wheeler, Ronald C. Chen, Deborah K. Mayer, Jessica C. Lyons and Bryce B. Reeve

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29205

      Although cancer diagnosis and treatment have a negative impact on individuals' lives regardless of race/ethnicity, among a group of patients with cancer (compared with a noncancer control group), the gap between racial/ethnic groups narrows before and after cancer diagnosis for some health-related quality-of-life measures. A greater understanding of the reasons why the racial/ethnic gap narrows is needed and can help inform initiatives to manage health-related quality of life among elderly cancer survivors in the United States.

    4. Disparities Research
      Practice adaptive reserve and colorectal cancer screening best practices at community health center clinics in 7 states

      Shin–Ping Tu, Vicki M. Young, Letoynia J. Coombs, Rebecca S. Williams, Michelle C. Kegler, Amanda T. Kimura, Betsy C. Risendal, Daniela B. Friedman, Beth A. Glenn, Debbie J. Pfeiffer and Maria E. Fernandez

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29176

      Enhancing the capability of community health centers to implement best practices may mitigate health disparities. A higher adaptive reserve, as measured by the practice adaptive reserve score, is positively associated with self-reported implementation of patient-centered medical home colorectal cancer screening best practices by clinic staff.

    5. Clinical Trials
      Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors

      David J. Vaughn, Wei-Ting Hwang, Priti Lal, Mark A. Rosen, Maryann Gallagher and Peter J. O'Dwyer

      Article first published online: 18 DEC 2014 | DOI: 10.1002/cncr.29213

      The retinoblastoma pathway is important in germ cell tumor biology and in the development of the platinum-resistant phenotype. In patients with incurable teratomas, the cyclin-dependent kinase 4/6 inhibitor palbociclib demonstrates promising activity, and further investigation is suggested.

  18. Commentary

    1. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer

      Conor E. Steuer, Fadlo R. Khuri and Suresh S. Ramalingam

      Article first published online: 17 DEC 2014 | DOI: 10.1002/cncr.29139

      Resistance to first-generation and second-generation epidermal growth factor receptor (EGFR) inhibitors eventually develops in patients with EGFR-mutated non-small cell lung cancer. However, a new generation of EGFR inhibitors are currently in clinical trials and are demonstrating promising efficacy in this patient population.

    2. The importance of disclosure: Lesbian, gay, bisexual, transgender/transsexual, queer/questioning, and intersex individuals and the cancer continuum

      Gwendolyn P. Quinn, Matthew B. Schabath, Julian A. Sanchez, Steven K. Sutton and B. Lee Green

      Article first published online: 17 DEC 2014 | DOI: 10.1002/cncr.29203

  19. Erratum

    1. You have free access to this content
  20. Original Articles

    1. Disease Site

      Head and Neck Disease
      Increasing time to treatment initiation for head and neck cancer: An analysis of the National Cancer Database

      Colin T. Murphy, Thomas J. Galloway, Elizabeth A. Handorf, Lora Wang, Ranee Mehra, Douglas B. Flieder and John A. Ridge

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29191

      In a cohort of over 270,000 people in the National Cancer Database, the current study identifies trends and risk factors for the increasing time to initiation of definitive treatment for head and neck cancer in the United States.

    2. Gastrointestinal Disease
      RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer

      Rona Yaeger, Elizabeth Cowell, Joanne F. Chou, Alexandra N. Gewirtz, Laetitia Borsu, Efsevia Vakiani, David B. Solit, Neal Rosen, Marinela Capanu, Marc Ladanyi and Nancy Kemeny

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29196

      In an analysis of a large series of genetically annotated, metastatic colorectal cancer cases, we find that patients whose tumors harbor a RAS mutation experience shorter overall survival and a significantly higher cumulative incidence of brain, bone, and lung metastases, while the presence of a PIK3CA mutation does not predict for worse outcomes or a site-specific pattern of metastatic spread. These data suggest a role for RAS activation in tumor metastatic progression and may help inform physicians' assessment of symptoms in patients with metastatic colorectal cancer.

    3. Discipline

      Epidemiology
      Insurance status and risk of cancer mortality among adolescents and young adults

      Abby R. Rosenberg, Leah Kroon, Lu Chen, Christopher I. Li and Barbara Jones

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29187

      Adolescents and young adults with nonprivate insurance or no insurance are more likely to present with advanced stages of cancer at diagnosis and to have higher cancer-related mortality, even if they were diagnosed initially with lower stage disease. Broader insurance coverage and access to health care may improve some of the disparate outcomes of adolescents and young adults with cancer.

  21. Editorials

  22. Commentary

    1. Cancer disparities research: It is time to come of age

      Michael T. Halpern

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29192

      Although cancer disparities research has been an extremely productive field, much of this research has been largely descriptive. Researchers need to prioritize disparity areas with knowledge gaps and focus on understanding both the causes of and approaches to addressing and reducing disparities.

  23. Original Articles

    1. Discipline

      Outcomes Research
      Cost-effectiveness of patient navigation to increase adherence with screening colonoscopy among minority individuals

      Uri Ladabaum, Ajitha Mannalithara, Lina Jandorf and Steven H. Itzkowitz

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29162

      Navigation increases uptake of screening colonoscopy among minority individuals. The results from this study suggest that navigation in a longitudinal screening colonoscopy program is likely to be cost effective, and that 1-time navigation in previously unscreened indivaduals may be cost saving.

    2. Disease Site

      Genitourinary Disease
      Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?

      Zachary Klaassen, Abhay A. Singh, Lauren E. Howard, Zhaoyong Feng, Bruce Trock, Martha K. Terris, William J. Aronson, Matthew R. Cooperberg, Christopher L. Amling, Christopher J. Kane, Alan Partin, Misop Han and Stephen J. Freedland

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29147

      The risk of biochemical recurrence for patients with clinical stage T2c disease without other high-risk features is comparable to the risk for men with intermediate-risk prostate cancer and significantly better than the risk for men with high-risk prostate cancer. Men with clinical stage T2c prostate cancer should be offered treatment options for intermediate-risk disease.

    3. Gastrointestinal Disease
      Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma

      William H. Sherman, Kyung Chu, John Chabot, John Allendorf, Beth Ann Schrope, Elizabeth Hecht, Brian Jin, David Leung, Helen Remotti, Gisella Addeo, Inna Postolov, Wei Tsai and Robert L. Fine

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29112

      Gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy can downstage more than 85% of patients with locally advanced pancreatic cancer so that more than 60% can achieve an R0 resection. This neoadjuvant regimen leads to a median survival greater than 29 months in those with arterial involvement, with more than 23% alive and disease-free beyond 32 months.

    4. Hematologic Malignancies
      Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

      Bouthaina S. Dabaja, Ann M. Vanderplas, Allison L. Crosby-Thompson, Gregory A. Abel, Myron S. Czuczman, Jonathan W. Friedberg, Leo I. Gordon, Mark Kaminski, Joyce Niland, Michael Millenson, Auayporn P. Nademanee, Andrew Zelenetz, Ann S. LaCasce and Maria Alma Rodriguez

      Article first published online: 9 DEC 2014 | DOI: 10.1002/cncr.29113

      The potential impact of consolidation on the overall survival and failure-free survival of patients with diffuse large B-cell lymphoma has been evaluated. Patients who receive consolidation radiation therapy are associated with a nonsignificant trend of higher overall survival and failure-free survival rates after adjustments for confounding factors.

    5. Discipline

      Disparities Research
      US breast cancer mortality trends in young women according to race

      Foluso O. Ademuyiwa, Feng Gao, Lin Hao, Daniel Morgensztern, Rebecca L. Aft, Cynthia X. Ma and Matthew J. Ellis

      Article first published online: 5 DEC 2014 | DOI: 10.1002/cncr.29178

      Among young women diagnosed with breast cancer, black patients have a worse outcome than white patients. Mortality declines have been observed over time in both racial groups, although more rapid gains have been noted to occur among white women.

  24. Correspondence

    1. Reply to US lung cancer trends by histologic type

      Denise Riedel Lewis, William D. Travis and Susan S. Devesa

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29179

    2. US lung cancer trends by histologic type

      Manali I. Patel, Iona Cheng and Scarlett Lin Gomez

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29180

  25. Original Articles

    1. Discipline

      Disparities Research
      Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: A single center study

      Vishal Bhatnagar, Yin Wu, Olga G. Goloubeva, Kathleen T. Ruehle, Todd E. Milliron, Carolynn G. Harris, Aaron P. Rapoport, Saul Yanovich, Edward A. Sausville, Maria R. Baer and Ashraf Z. Badros

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29160

      In a retrospective review of patients with multiple myeloma treated at the study institution, there were notable differences in disease characteristics between black and white patients. Race also impacts overall survival, response to induction, and maintenance therapies.

    2. Clinical Trials
      SIS.NET: A randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer

      Alyse E. Wheelock, Meredith A. Bock, Eva L. Martin, Jimmy Hwang, Mary Lou Ernest, Hope S. Rugo, Laura J. Esserman and Michelle E. Melisko

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29088

      The results of this randomized controlled trial found that a Web-based system to facilitate symptom management among survivors of breast cancer did not lead to lower appointment frequency. However, Web-based tools to track patient symptoms may help to provide more efficient symptom management.

    3. Quality of Life
      Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation

      Areej R. El-Jawahri, Lara N. Traeger, Kailyn Kuzmuk, Justin R. Eusebio, Harry B. Vandusen, Jennifer A. Shin, Tanya Keenan, Emily R. Gallagher, Joseph A. Greer, William F. Pirl, Vicki A. Jackson, Karen K. Ballen, Thomas R. Spitzer, Timothy A. Graubert, Steven L. McAfee, Bimalangshu R. Dey, Yi-Bin A. Chen and Jennifer S. Temel

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29149

      Patients undergoing hematopoietic stem cell transplantation reported a steep deterioration in quality of life and substantially worsening depression during hospitalization. Baseline anxiety and depression were found to predict worse quality of life during hospitalization, underscoring the importance of assessing psychiatric morbidity prior to hematopoietic stem cell transplantation.

    4. Translational Research
      Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis

      Qiuling Shi, Xin Shelley Wang, Guojun Li, Nina D. Shah, Robert Z. Orlowski, Loretta A. Williams, Tito R. Mendoza and Charles S. Cleeland

      Article first published online: 2 DEC 2014 | DOI: 10.1002/cncr.29154

      Predictors of symptom burden in patients with multiple myeloma after 1 year of therapy and possible associations between symptom burden and regulatory single-nucleotide polymorphisms in several inflammatory genes are investigated. Genetic markers may identify patients at risk for severe symptoms early in their cancer or treatment trajectory, and this could foster more effective symptom control.

    5. Disease Site

      Endocrine Disease
      Should small papillary thyroid cancer be observed? A population-based study

      Naris Nilubol and Electron Kebebew

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29123

      Nonoperative management should be used with caution for patients who have papillary thyroid cancers that measure ≤2 cm in greatest dimension. Patients aged ≥45 years with papillary thyroid cancers ≤2 cm should undergo thyroidectomy.

    6. Discipline

      Radiation Oncology
      A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer

      Penny Fang, Rosemarie Mick, Curtiland Deville, Stefan Both, Justin E. Bekelman, John P. Christodouleas, Thomas J. Guzzo, Zelig Tochner, Stephen M. Hahn and Neha Vapiwala

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29148

      In this patient-level, matched comparison of prospectively collected toxicity data on patietns with localized prostate carcinoma who received treated with contemporary IMRT and PBT techniques and similar dose-fractionation regimens, risks of acute and late GI and GU toxicities were not significantly different after careful adjustment for confounders and predictive factors.

  26. Erratum

    1. You have free access to this content
      Erratum

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29118

      This article corrects:
  27. Original Articles

    1. Disease Site

      Hematologic Malignancies
      Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

      Frédéric Baron, Myriam Labopin, Andy Peniket, Pavel Jindra, Boris Afanasyev, Miguel A. Sanz, Eric Deconinck, Arnon Nagler and Mohamad Mohty

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29163

      Fludarabine and melphalan provide better acute myeloid leukemia control than fludarabine and busulfan as a reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation. Fludarabine plus busulfan and fludarabine plus melphalan provide similar overall survival.

    2. Discipline

      Epidemiology
      Metformin for primary colorectal cancer prevention in patients with diabetes: A case-control study in a US population

      Amikar Sehdev, Ya-Chen T. Shih, Benjamin Vekhter, Marc B. Bissonnette, Olufunmilayo I. Olopade and Blase N. Polite

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29165

      The use of metformin is associated with a reduced risk of developing colorectal cancer among patients with diabetes in the US population. Further studies are needed to understand the mechanism of action and the development of metformin for clinical use.

  28. Correspondence

  29. Erratum

    1. You have free access to this content
      Erratum

      Article first published online: 25 NOV 2014 | DOI: 10.1002/cncr.29151

      This article corrects:

      IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma

      Vol. 120, Issue 24, 3952–3957, Article first published online: 12 AUG 2014

  30. Original Articles

    1. Disease Site

      Genitourinary Disease
      Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance)

      Jai N. Patel, Chen Jiang, Daniel L. Hertz, Flora A. Mulkey, Kouros Owzar, Susan Halabi, Mark J. Ratain, Paula N. Friedman, Eric J. Small, Michael A. Carducci, John F. Mahoney, Michael J. Kelley, Michael J. Morris, William K. Kelly and Howard L. McLeod

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29169

      The authors demonstrate that bevacizumab treatment is significantly associated with arterial thromboembolism (ATE) only, and not with venous thromboembolism (VTE). In addition, results from this study indicate that increasing age is significantly associated with the risk of both ATE and VTE in patients with prostate cancer, whereas the VTE risk score, which incorporates leukocyte count, hemoglobin, platelet count, body mass index, and tumor location, is significantly associated with the risk of VTE.

    2. Hematologic Malignancies
      Perinatal and familial risk factors for acute lymphoblastic leukemia in a Swedish national cohort

      Casey Crump, Jan Sundquist, Weiva Sieh, Marilyn A. Winkleby and Kristina Sundquist

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29172

      The authors conducted what to their knowledge is the largest population-based cohort study to date to examine perinatal and familial risk factors for acute lymphoblastic leukemia (ALL) among approximately 3.5 million individuals born in Sweden between 1973 and 2008. High fetal growth was found to be associated with an increased risk of ALL in childhood through young adulthood, independent of gestational age at birth, suggesting that growth factor pathways may play an important long-term role in the etiology of ALL.

  31. Editorials

    1. Bevicizumab and thrombosis: Some answers but questions remain

      Thomas G. DeLoughery and Tomasz M. Beer

      Article first published online: 21 NOV 2014 | DOI: 10.1002/cncr.29168

      The study by Patel and colleagues reported in this issue verifies the increased risk of arterial thrombosis, but not venous thrombosis, with the receipt of bevacizumab. The focus of future research now needs to be on ameliorating this increased risk and identifying the mechanism for prothrombotic effects of targeted antineoplastic therapy.

  32. Original Articles

    1. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumors

      Johanna C. Bendell, Manish R. Patel, Jeffrey R. Infante, Carla D. Kurkjian, Suzanne F. Jones, Shubham Pant, Howard A. Burris III, Ofir Moreno, Vanessa Esquibel, Wendy Levin and Kathleen N. Moore

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29155

      The current phase 1, open-label, dose escalating, first-in human study of ME-344 in patients with refractory solid tumors found that the maximum tolerated dose of once-weekly 10-mg/kg administration of the drug was generally well tolerated. The preliminary clinical activity as a monotherapy supports the further clinical development of ME-344 in combination with chemotherapy.

    2. Epidemiology
      Quality of life over 5 years after a breast cancer diagnosis among low-income women: Effects of race/ethnicity and patient-physician communication

      Rose C. Maly, Yihang Liu, Li-Jung Liang and Patricia A. Ganz

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29150

      The current study is among the first and largest studies to examine risk factors for poorer quality of life among newly diagnosed, low-income women with breast cancer over time. The results suggest that quality of life in this vulnerable population could be particularly improved by targeted interventions aimed at increasing physician information-giving and empowering patients in communicating with physicians, as well as by attention to comorbid medical conditions.

    3. Disease Site

      Genitourinary Disease
      Impact of biochemical failure classification on clinical outcome: A secondary analysis of Radiation Therapy Oncology Group 9202 and 9413

      Daniel A. Hamstra, Kyounghwa Bae, Gerald Hanks, Chen Hu, William U. Shipley, Charlie C. Pan, Mack Roach III, Colleen A. Lawton and Howard M. Sandler

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29146

      After radiation therapy, biochemical failure is defined on the basis of either rising prostate-specific antigen levels or the initiation of salvage androgen ablation for other reasons. Patients started on salvage androgen therapy without meeting the criteria for rising prostate-specific antigen levels may have worse clinical outcomes; as such, those with rising prostate-specific antigen levels only may actually represent a more favorable group of patients.

    4. Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer

      Hung-Jui Tan, Anne-Marie Meyer, Tzy-Mey Kuo, Angela B. Smith, Stephanie B. Wheeler, William R. Carpenter and Matthew E. Nielsen

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29144

      Provider-based research networks such as the Community Clinical Oncology Program offer a potential conduit for the diffusion of technology into the treatment of patients with cancer. However, the utilization of laparoscopy and partial nephrectomy for kidney cancer did not differ according to the Community Clinical Oncology Program affiliation status, and this indicates potential limits of provider-based research networks in translating evidence-based cancer care into clinical practice.

    5. Hematologic Malignancies
      Outcome of Patients With Low-Risk and Intermediate-1—Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure: A Report on Behalf of the MDS Clinical Research Consortium

      Elias J. Jabbour, Guillermo Garcia-Manero, Paolo Strati, Asmita Mishra, Najla H. Al Ali, Eric Padron, Jeffrey Lancet, Tapan Kadia, Naval Daver, Susan O'Brien, David P. Steensma, Mikkael A. Sekeres, Steven D. Gore, Amy Dezern, Gail J. Roboz, Alan F. List, Hagop M. Kantarjian and Rami S. Komrokji

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29145

      The outcomes of patients with lower-risk myelodysplastic syndromes after treatment failure with hypomethylating agents are poor, with a median survival of 17 months reported. Overall survival is a reasonable primary endpoint for clinical studies targeting this patient population.

  33. Editorials

    1. Struggles in exporting complex surgical advances

      Christopher Weight

      Article first published online: 19 NOV 2014 | DOI: 10.1002/cncr.29143

      The diffusion of complex surgical innovations is challenging and slow and, in some cases, may not be in the patient's best interest. Perhaps better patient education and empowerment will allow the best care at lower cost.

  34. Original Articles

    1. Discipline

      Disparities Research
      Video-based educational tool improves patient comprehension of common prostate health terminology

      Daniel S. Wang, Ashesh B. Jani, Musu Sesay, Caroline G. Tai, Daniel K. Lee, Katharina V. Echt, Michael G. Goodman, Kerry E. Kilbridge and Viraj A. Master

      Article first published online: 12 NOV 2014 | DOI: 10.1002/cncr.29101

      Recent studies have revealed a disheartening lack of comprehension of medical terms often used in counseling patients about treatment options. To address this vital component of shared decision making, a video-based educational tool has been developed, and it results in significant gains in patient comprehension of such terminology.

    2. Disease Site

      Hematologic Malignancies
      Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?

      Fuad El Rassi, John D. Bergsagel, Martha Arellano, Manila Gaddh, Anand Jillella, Vamsi Kota, Leonard T. Heffner, Elliott F. Winton and Hanna Jean Khoury

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29142

      Flow cytometry (FC) is a commonly requested test in the workup of leukocytosis in community practices, and the role of FC in chronic-phase chronic myeloid leukemia (CP-CML) is unknown. In contrast to the detection of aberrant myeloid markers, the detection of lymphoid markers by FC at the time of the diagnosis of CP-CML appears to be associated with early progression to the lymphoid blast phase.

    3. Soft Tissue and Bone Sarcoma
      Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma—Associations with tumor phenotype and survival

      Jason U. Tilan, Mark Krailo, Donald A. Barkauskas, Susana Galli, Haifa Mtaweh, Jessica Long, Hongkun Wang, Kirsten Hawkins, Congyi Lu, Dima Jeha, Ewa Izycka-Swieszewska, Elizabeth R. Lawlor, Jeffrey A. Toretsky and Joanna B. Kitlinska

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29090

      Elevated systemic levels of neuropeptide Y, an EWS-FLI1 transcriptional target that is highly expressed in Ewing sarcoma, are associated with unfavorable clinical features, such as pelvic localization, the presence of metastases, and bone origin. Conversely, high activity of dipeptidyl peptidase IV in patients' sera is associated with a better prognosis, suggesting a potential role for the protease in antitumor immune response.

    4. Discipline

      Complementary Medicine
      Cancer survivors' disclosure of complementary health approaches to physicians: The role of patient-centered communication

      Stephanie J. Sohl, Laurel A. Borowski, Erin E. Kent, Ashley Wilder Smith, Ingrid Oakley-Girvan, Russell L. Rothman and Neeraj K. Arora

      Article first published online: 11 NOV 2014 | DOI: 10.1002/cncr.29138

      Analyses of a population-based sample of cancer survivors support the idea that improving the overall patient centeredness of cancer follow-up care and improving the disclosure of complementary health approaches to physicians are potentially synergistic clinical goals.

VIEW

  1. 1 - 100
  2. 101 - 147

SEARCH

SEARCH BY CITATION